SPOTLIGHT: Thailand reconsiders compulsory licenses

Thailand's new public health minister has pledged to review his country's compulsory licensing of four cancer medicines--two made by Novartis, one by Sanofi-Aventis, and another by Roche. Under the previous minister, Thailand was aggressively using compulsory licenses to circumvent patent protection on drugs so it could obtain lower-cost versions. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.